Linsitinib (OSI-906) for the treatment of Adult and Pediatric Wild Type Gastrointestinal Stromal Tumors, a SARC Phase II study.
Most GISTs have activating mutations of KIT, PDGFRA, or uncommonly BRAF. Fifteen percent of adult and 85% of pediatric GIST are wild type (WT), commonly having high expression of IGF-1R and loss of succinate dehydrogenase (SDH) complex function. We tested the efficacy of linsitinib, an oral TKI IGF-1R inhibitor in WT GIST patients. A multi-center phase II trial of linsitinib was conducted. The primary endpoint was objective response rate. Secondary endpoints were clinical benefit rate: CR, PR and SD≥9 months, and quantitative FDG metabolic response (MR) at week 8. Serum levels for glucose, insulin, IGF-1R ligand IGF1, and binding proteins were obtained to explore correlations to patient outcomes and FDG-PET results. Twenty patients were accrued in a 6 month period. Grade 3-4 toxicities possibly related to linsitinib were uncommon (8.5%). No objective responses were seen. CBR at 9 months was 40%. Intense FDG uptake was observed at baseline, with partial MR of 12% and stable MD of 65% at week 8; these patients had RECIST 1.1 SD as their best response. PFS and OS Kaplan Meier estimates at 9 months were 52% and 80%, respectively. SDHA/B loss determined by immunohistochemistry was seen in 35% and 88% of cases, respectively. Linsitinib is well tolerated in patients with WT GIST. While the 9 month CBR was 40%, and PFS at 9 months was 52%, no objective responses were observed. Rapid accrual to this study demonstrates clinical trials of experimental agents in selected subtypes of GIST are feasible.